TP53 and acquired polycythemia vera: MIPSS-ET and -PV are available for classifying the prognostic risks of patients with ET and PV, using the SF3B1, SRSF2, TP53, and U2AF1 mutations for ET and the SRSF2 mutation for PV [54].